nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—PGD—Furosemide—dilated cardiomyopathy	0.298	0.392	CbGbCtD
Methotrexate—SLC22A11—Furosemide—dilated cardiomyopathy	0.0882	0.116	CbGbCtD
Methotrexate—SLCO1A2—Spironolactone—dilated cardiomyopathy	0.0863	0.114	CbGbCtD
Methotrexate—ABCC2—Spironolactone—dilated cardiomyopathy	0.0715	0.0941	CbGbCtD
Methotrexate—SLC22A8—Furosemide—dilated cardiomyopathy	0.0513	0.0676	CbGbCtD
Methotrexate—ABCC2—Furosemide—dilated cardiomyopathy	0.0489	0.0643	CbGbCtD
Methotrexate—SLC22A6—Furosemide—dilated cardiomyopathy	0.0358	0.0471	CbGbCtD
Methotrexate—ALB—Furosemide—dilated cardiomyopathy	0.0305	0.0401	CbGbCtD
Methotrexate—ABCB1—Lisinopril—dilated cardiomyopathy	0.0265	0.0349	CbGbCtD
Methotrexate—ABCB1—Spironolactone—dilated cardiomyopathy	0.0233	0.0307	CbGbCtD
Methotrexate—Hepatic cirrhosis—Furosemide—dilated cardiomyopathy	0.00512	0.0417	CcSEcCtD
Methotrexate—Dry cough—Lisinopril—dilated cardiomyopathy	0.00476	0.0388	CcSEcCtD
Methotrexate—FPGS—cardiac ventricle—dilated cardiomyopathy	0.00229	0.0621	CbGeAlD
Methotrexate—SLC19A1—heart—dilated cardiomyopathy	0.00226	0.0612	CbGeAlD
Methotrexate—Diabetic—Lisinopril—dilated cardiomyopathy	0.00221	0.018	CcSEcCtD
Methotrexate—Anuria—Lisinopril—dilated cardiomyopathy	0.00211	0.0172	CcSEcCtD
Methotrexate—Ulcer—Spironolactone—dilated cardiomyopathy	0.00191	0.0156	CcSEcCtD
Methotrexate—Vasculitis—Spironolactone—dilated cardiomyopathy	0.00185	0.0151	CcSEcCtD
Methotrexate—GGH—heart—dilated cardiomyopathy	0.00171	0.0464	CbGeAlD
Methotrexate—SLCO3A1—cardiac ventricle—dilated cardiomyopathy	0.00162	0.0439	CbGeAlD
Methotrexate—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.00161	0.0132	CcSEcCtD
Methotrexate—Eruption—Furosemide—dilated cardiomyopathy	0.0016	0.013	CcSEcCtD
Methotrexate—Lung infiltration—Lisinopril—dilated cardiomyopathy	0.00157	0.0128	CcSEcCtD
Methotrexate—SLCO3A1—myocardium—dilated cardiomyopathy	0.00153	0.0413	CbGeAlD
Methotrexate—FPGS—heart—dilated cardiomyopathy	0.00151	0.0408	CbGeAlD
Methotrexate—DHFR—cardiac ventricle—dilated cardiomyopathy	0.00149	0.0403	CbGeAlD
Methotrexate—Appetite absent—Lisinopril—dilated cardiomyopathy	0.00148	0.0121	CcSEcCtD
Methotrexate—ATIC—heart—dilated cardiomyopathy	0.00146	0.0394	CbGeAlD
Methotrexate—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00142	0.0116	CcSEcCtD
Methotrexate—DHFR—myocardium—dilated cardiomyopathy	0.0014	0.0379	CbGeAlD
Methotrexate—Azotaemia—Lisinopril—dilated cardiomyopathy	0.00138	0.0113	CcSEcCtD
Methotrexate—PGD—myocardium—dilated cardiomyopathy	0.00135	0.0365	CbGeAlD
Methotrexate—SLC16A1—cardiac ventricle—dilated cardiomyopathy	0.00134	0.0362	CbGeAlD
Methotrexate—Lethargy—Spironolactone—dilated cardiomyopathy	0.00134	0.0109	CcSEcCtD
Methotrexate—FPGS—cardiac atrium—dilated cardiomyopathy	0.00129	0.0349	CbGeAlD
Methotrexate—SLC16A1—myocardium—dilated cardiomyopathy	0.00126	0.034	CbGeAlD
Methotrexate—Ataxia—Spironolactone—dilated cardiomyopathy	0.00123	0.01	CcSEcCtD
Methotrexate—ABCC10—cardiac ventricle—dilated cardiomyopathy	0.00123	0.0332	CbGeAlD
Methotrexate—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00118	0.00962	CcSEcCtD
Methotrexate—Psoriasis—Lisinopril—dilated cardiomyopathy	0.00117	0.00955	CcSEcCtD
Methotrexate—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00112	0.00914	CcSEcCtD
Methotrexate—Bone marrow depression—Lisinopril—dilated cardiomyopathy	0.00109	0.0089	CcSEcCtD
Methotrexate—MTHFR—heart—dilated cardiomyopathy	0.00108	0.0293	CbGeAlD
Methotrexate—SLCO3A1—heart—dilated cardiomyopathy	0.00106	0.0288	CbGeAlD
Methotrexate—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00106	0.00863	CcSEcCtD
Methotrexate—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00104	0.0085	CcSEcCtD
Methotrexate—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00101	0.00823	CcSEcCtD
Methotrexate—Vasculitis—Furosemide—dilated cardiomyopathy	0.00101	0.0082	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.001	0.00816	CcSEcCtD
Methotrexate—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.001	0.00815	CcSEcCtD
Methotrexate—Renal failure—Spironolactone—dilated cardiomyopathy	0.000992	0.00809	CcSEcCtD
Methotrexate—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.000978	0.00798	CcSEcCtD
Methotrexate—DHFR—heart—dilated cardiomyopathy	0.000978	0.0265	CbGeAlD
Methotrexate—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.000962	0.00784	CcSEcCtD
Methotrexate—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.000942	0.00768	CcSEcCtD
Methotrexate—PGD—heart—dilated cardiomyopathy	0.00094	0.0255	CbGeAlD
Methotrexate—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.000922	0.00751	CcSEcCtD
Methotrexate—SLCO3A1—cardiac atrium—dilated cardiomyopathy	0.000911	0.0247	CbGeAlD
Methotrexate—Urine output increased—Furosemide—dilated cardiomyopathy	0.000888	0.00724	CcSEcCtD
Methotrexate—Bladder pain—Furosemide—dilated cardiomyopathy	0.000888	0.00724	CcSEcCtD
Methotrexate—SLC16A1—heart—dilated cardiomyopathy	0.000878	0.0238	CbGeAlD
Methotrexate—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.000857	0.00699	CcSEcCtD
Methotrexate—Proteinuria—Lisinopril—dilated cardiomyopathy	0.000838	0.00683	CcSEcCtD
Methotrexate—DHFR—cardiac atrium—dilated cardiomyopathy	0.000836	0.0226	CbGeAlD
Methotrexate—AOX1—heart—dilated cardiomyopathy	0.000828	0.0224	CbGeAlD
Methotrexate—Protein urine present—Lisinopril—dilated cardiomyopathy	0.000827	0.00674	CcSEcCtD
Methotrexate—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.000823	0.00671	CcSEcCtD
Methotrexate—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.000819	0.00668	CcSEcCtD
Methotrexate—ABCC1—myocardium—dilated cardiomyopathy	0.000817	0.0221	CbGeAlD
Methotrexate—Polyuria—Furosemide—dilated cardiomyopathy	0.000812	0.00662	CcSEcCtD
Methotrexate—Photosensitivity—Furosemide—dilated cardiomyopathy	0.000812	0.00662	CcSEcCtD
Methotrexate—ABCC10—heart—dilated cardiomyopathy	0.000806	0.0218	CbGeAlD
Methotrexate—PGD—cardiac atrium—dilated cardiomyopathy	0.000804	0.0218	CbGeAlD
Methotrexate—Alopecia—Spironolactone—dilated cardiomyopathy	0.000801	0.00653	CcSEcCtD
Methotrexate—Oliguria—Lisinopril—dilated cardiomyopathy	0.000799	0.00652	CcSEcCtD
Methotrexate—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.000755	0.00616	CcSEcCtD
Methotrexate—Vasculitis—Lisinopril—dilated cardiomyopathy	0.000755	0.00615	CcSEcCtD
Methotrexate—SLC16A1—cardiac atrium—dilated cardiomyopathy	0.000751	0.0203	CbGeAlD
Methotrexate—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.000737	0.00601	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.000736	0.006	CcSEcCtD
Methotrexate—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.000732	0.00597	CcSEcCtD
Methotrexate—Lethargy—Furosemide—dilated cardiomyopathy	0.000727	0.00593	CcSEcCtD
Methotrexate—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00072	0.00587	CcSEcCtD
Methotrexate—Malaise—Spironolactone—dilated cardiomyopathy	0.000711	0.0058	CcSEcCtD
Methotrexate—Cystitis—Lisinopril—dilated cardiomyopathy	0.000711	0.0058	CcSEcCtD
Methotrexate—AOX1—cardiac atrium—dilated cardiomyopathy	0.000708	0.0192	CbGeAlD
Methotrexate—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000706	0.00576	CcSEcCtD
Methotrexate—ALB—heart—dilated cardiomyopathy	0.000691	0.0187	CbGeAlD
Methotrexate—ABCC10—cardiac atrium—dilated cardiomyopathy	0.000689	0.0187	CbGeAlD
Methotrexate—Irritability—Furosemide—dilated cardiomyopathy	0.00068	0.00555	CcSEcCtD
Methotrexate—ABCC4—heart—dilated cardiomyopathy	0.000669	0.0181	CbGeAlD
Methotrexate—Bladder pain—Lisinopril—dilated cardiomyopathy	0.000666	0.00543	CcSEcCtD
Methotrexate—Discomfort—Spironolactone—dilated cardiomyopathy	0.000664	0.00541	CcSEcCtD
Methotrexate—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.000656	0.00535	CcSEcCtD
Methotrexate—Confusional state—Spironolactone—dilated cardiomyopathy	0.000649	0.00529	CcSEcCtD
Methotrexate—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000644	0.00525	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.000642	0.00523	CcSEcCtD
Methotrexate—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00063	0.00514	CcSEcCtD
Methotrexate—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.000615	0.00501	CcSEcCtD
Methotrexate—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00061	0.00497	CcSEcCtD
Methotrexate—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.000609	0.00496	CcSEcCtD
Methotrexate—Pancreatitis—Furosemide—dilated cardiomyopathy	0.000604	0.00492	CcSEcCtD
Methotrexate—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.000595	0.00485	CcSEcCtD
Methotrexate—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.000579	0.00472	CcSEcCtD
Methotrexate—Somnolence—Spironolactone—dilated cardiomyopathy	0.000572	0.00467	CcSEcCtD
Methotrexate—ABCC1—heart—dilated cardiomyopathy	0.00057	0.0154	CbGeAlD
Methotrexate—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000562	0.00458	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000556	0.00453	CcSEcCtD
Methotrexate—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.000552	0.0045	CcSEcCtD
Methotrexate—Drowsiness—Furosemide—dilated cardiomyopathy	0.000549	0.00448	CcSEcCtD
Methotrexate—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.000546	0.00445	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.000544	0.00444	CcSEcCtD
Methotrexate—Renal failure—Furosemide—dilated cardiomyopathy	0.00054	0.0044	CcSEcCtD
Methotrexate—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.000535	0.00436	CcSEcCtD
Methotrexate—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000531	0.00433	CcSEcCtD
Methotrexate—Sweating—Furosemide—dilated cardiomyopathy	0.000526	0.00429	CcSEcCtD
Methotrexate—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000519	0.00423	CcSEcCtD
Methotrexate—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.000513	0.00418	CcSEcCtD
Methotrexate—Urticaria—Spironolactone—dilated cardiomyopathy	0.000511	0.00417	CcSEcCtD
Methotrexate—Irritability—Lisinopril—dilated cardiomyopathy	0.00051	0.00416	CcSEcCtD
Methotrexate—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000509	0.00415	CcSEcCtD
Methotrexate—Ataxia—Lisinopril—dilated cardiomyopathy	0.000503	0.0041	CcSEcCtD
Methotrexate—ABCC1—cardiac atrium—dilated cardiomyopathy	0.000488	0.0132	CbGeAlD
Methotrexate—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000487	0.00397	CcSEcCtD
Methotrexate—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000483	0.00394	CcSEcCtD
Methotrexate—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000483	0.00394	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000481	0.00393	CcSEcCtD
Methotrexate—Visual impairment—Furosemide—dilated cardiomyopathy	0.000475	0.00387	CcSEcCtD
Methotrexate—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000474	0.00387	CcSEcCtD
Methotrexate—ABCG2—heart—dilated cardiomyopathy	0.000472	0.0128	CbGeAlD
Methotrexate—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000466	0.0038	CcSEcCtD
Methotrexate—Asthma—Lisinopril—dilated cardiomyopathy	0.000462	0.00377	CcSEcCtD
Methotrexate—Eye disorder—Furosemide—dilated cardiomyopathy	0.000461	0.00376	CcSEcCtD
Methotrexate—Tinnitus—Furosemide—dilated cardiomyopathy	0.00046	0.00375	CcSEcCtD
Methotrexate—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.000458	0.00373	CcSEcCtD
Methotrexate—Pruritus—Spironolactone—dilated cardiomyopathy	0.000455	0.00371	CcSEcCtD
Methotrexate—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000453	0.00369	CcSEcCtD
Methotrexate—Angiopathy—Furosemide—dilated cardiomyopathy	0.000447	0.00365	CcSEcCtD
Methotrexate—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000445	0.00363	CcSEcCtD
Methotrexate—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00044	0.00359	CcSEcCtD
Methotrexate—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000439	0.00358	CcSEcCtD
Methotrexate—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000432	0.00352	CcSEcCtD
Methotrexate—Dysuria—Lisinopril—dilated cardiomyopathy	0.000432	0.00352	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00043	0.0035	CcSEcCtD
Methotrexate—Malnutrition—Furosemide—dilated cardiomyopathy	0.000429	0.0035	CcSEcCtD
Methotrexate—Erythema—Furosemide—dilated cardiomyopathy	0.000429	0.0035	CcSEcCtD
Methotrexate—Dizziness—Spironolactone—dilated cardiomyopathy	0.000426	0.00347	CcSEcCtD
Methotrexate—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000426	0.00347	CcSEcCtD
Methotrexate—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000422	0.00344	CcSEcCtD
Methotrexate—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00042	0.00343	CcSEcCtD
Methotrexate—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000414	0.00338	CcSEcCtD
Methotrexate—Depression—Lisinopril—dilated cardiomyopathy	0.000411	0.00335	CcSEcCtD
Methotrexate—Vomiting—Spironolactone—dilated cardiomyopathy	0.000409	0.00334	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000409	0.00333	CcSEcCtD
Methotrexate—Rash—Spironolactone—dilated cardiomyopathy	0.000406	0.00331	CcSEcCtD
Methotrexate—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000406	0.00331	CcSEcCtD
Methotrexate—Renal failure—Lisinopril—dilated cardiomyopathy	0.000405	0.0033	CcSEcCtD
Methotrexate—Vision blurred—Furosemide—dilated cardiomyopathy	0.000404	0.0033	CcSEcCtD
Methotrexate—Headache—Spironolactone—dilated cardiomyopathy	0.000403	0.00329	CcSEcCtD
Methotrexate—Anaemia—Furosemide—dilated cardiomyopathy	0.000397	0.00323	CcSEcCtD
Methotrexate—Sweating—Lisinopril—dilated cardiomyopathy	0.000395	0.00322	CcSEcCtD
Methotrexate—Haematuria—Lisinopril—dilated cardiomyopathy	0.000393	0.0032	CcSEcCtD
Methotrexate—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00039	0.00318	CcSEcCtD
Methotrexate—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000389	0.00317	CcSEcCtD
Methotrexate—Vertigo—Furosemide—dilated cardiomyopathy	0.000386	0.00314	CcSEcCtD
Methotrexate—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000385	0.00313	CcSEcCtD
Methotrexate—Leukopenia—Furosemide—dilated cardiomyopathy	0.000384	0.00313	CcSEcCtD
Methotrexate—Nausea—Spironolactone—dilated cardiomyopathy	0.000382	0.00312	CcSEcCtD
Methotrexate—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00037	0.00302	CcSEcCtD
Methotrexate—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000367	0.00299	CcSEcCtD
Methotrexate—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000365	0.00298	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000363	0.00296	CcSEcCtD
Methotrexate—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000363	0.00296	CcSEcCtD
Methotrexate—Confusional state—Furosemide—dilated cardiomyopathy	0.000353	0.00288	CcSEcCtD
Methotrexate—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00035	0.00286	CcSEcCtD
Methotrexate—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00035	0.00285	CcSEcCtD
Methotrexate—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000345	0.00281	CcSEcCtD
Methotrexate—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000343	0.0028	CcSEcCtD
Methotrexate—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000343	0.0028	CcSEcCtD
Methotrexate—Skin disorder—Furosemide—dilated cardiomyopathy	0.00034	0.00277	CcSEcCtD
Methotrexate—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000339	0.00276	CcSEcCtD
Methotrexate—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000336	0.00274	CcSEcCtD
Methotrexate—Anorexia—Furosemide—dilated cardiomyopathy	0.000334	0.00272	CcSEcCtD
Methotrexate—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000333	0.00272	CcSEcCtD
Methotrexate—Chills—Lisinopril—dilated cardiomyopathy	0.000332	0.00271	CcSEcCtD
Methotrexate—Hypotension—Furosemide—dilated cardiomyopathy	0.000327	0.00267	CcSEcCtD
Methotrexate—Alopecia—Lisinopril—dilated cardiomyopathy	0.000327	0.00266	CcSEcCtD
Methotrexate—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000324	0.00264	CcSEcCtD
Methotrexate—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000322	0.00263	CcSEcCtD
Methotrexate—Erythema—Lisinopril—dilated cardiomyopathy	0.000322	0.00263	CcSEcCtD
Methotrexate—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000315	0.00257	CcSEcCtD
Methotrexate—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000315	0.00256	CcSEcCtD
Methotrexate—Back pain—Lisinopril—dilated cardiomyopathy	0.000311	0.00254	CcSEcCtD
Methotrexate—Somnolence—Furosemide—dilated cardiomyopathy	0.000311	0.00254	CcSEcCtD
Methotrexate—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000304	0.00248	CcSEcCtD
Methotrexate—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000303	0.00247	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000302	0.00247	CcSEcCtD
Methotrexate—Fatigue—Furosemide—dilated cardiomyopathy	0.000302	0.00246	CcSEcCtD
Methotrexate—Pain—Furosemide—dilated cardiomyopathy	0.0003	0.00244	CcSEcCtD
Methotrexate—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000299	0.00244	CcSEcCtD
Methotrexate—Anaemia—Lisinopril—dilated cardiomyopathy	0.000298	0.00243	CcSEcCtD
Methotrexate—Malaise—Lisinopril—dilated cardiomyopathy	0.00029	0.00237	CcSEcCtD
Methotrexate—Vertigo—Lisinopril—dilated cardiomyopathy	0.000289	0.00236	CcSEcCtD
Methotrexate—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000289	0.00235	CcSEcCtD
Methotrexate—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000288	0.00235	CcSEcCtD
Methotrexate—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000286	0.00234	CcSEcCtD
Methotrexate—Cough—Lisinopril—dilated cardiomyopathy	0.000281	0.00229	CcSEcCtD
Methotrexate—Urticaria—Furosemide—dilated cardiomyopathy	0.000278	0.00227	CcSEcCtD
Methotrexate—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000277	0.00226	CcSEcCtD
Methotrexate—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000277	0.00226	CcSEcCtD
Methotrexate—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000274	0.00223	CcSEcCtD
Methotrexate—Chest pain—Lisinopril—dilated cardiomyopathy	0.000274	0.00223	CcSEcCtD
Methotrexate—Myalgia—Lisinopril—dilated cardiomyopathy	0.000274	0.00223	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000272	0.00222	CcSEcCtD
Methotrexate—Discomfort—Lisinopril—dilated cardiomyopathy	0.000271	0.00221	CcSEcCtD
Methotrexate—Confusional state—Lisinopril—dilated cardiomyopathy	0.000265	0.00216	CcSEcCtD
Methotrexate—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000263	0.00214	CcSEcCtD
Methotrexate—Infection—Lisinopril—dilated cardiomyopathy	0.000261	0.00213	CcSEcCtD
Methotrexate—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000258	0.0021	CcSEcCtD
Methotrexate—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000257	0.0021	CcSEcCtD
Methotrexate—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000255	0.00208	CcSEcCtD
Methotrexate—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000254	0.00207	CcSEcCtD
Methotrexate—Asthenia—Furosemide—dilated cardiomyopathy	0.000251	0.00205	CcSEcCtD
Methotrexate—Anorexia—Lisinopril—dilated cardiomyopathy	0.000251	0.00204	CcSEcCtD
Methotrexate—Pruritus—Furosemide—dilated cardiomyopathy	0.000248	0.00202	CcSEcCtD
Methotrexate—Hypotension—Lisinopril—dilated cardiomyopathy	0.000246	0.002	CcSEcCtD
Methotrexate—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00024	0.00195	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000239	0.00195	CcSEcCtD
Methotrexate—Insomnia—Lisinopril—dilated cardiomyopathy	0.000238	0.00194	CcSEcCtD
Methotrexate—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000236	0.00192	CcSEcCtD
Methotrexate—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000234	0.00191	CcSEcCtD
Methotrexate—Somnolence—Lisinopril—dilated cardiomyopathy	0.000234	0.0019	CcSEcCtD
Methotrexate—ABCB1—heart—dilated cardiomyopathy	0.000233	0.0063	CbGeAlD
Methotrexate—Dizziness—Furosemide—dilated cardiomyopathy	0.000232	0.00189	CcSEcCtD
Methotrexate—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000231	0.00189	CcSEcCtD
Methotrexate—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000228	0.00186	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000227	0.00185	CcSEcCtD
Methotrexate—Fatigue—Lisinopril—dilated cardiomyopathy	0.000227	0.00185	CcSEcCtD
Methotrexate—Pain—Lisinopril—dilated cardiomyopathy	0.000225	0.00183	CcSEcCtD
Methotrexate—Vomiting—Furosemide—dilated cardiomyopathy	0.000223	0.00182	CcSEcCtD
Methotrexate—Rash—Furosemide—dilated cardiomyopathy	0.000221	0.0018	CcSEcCtD
Methotrexate—Dermatitis—Furosemide—dilated cardiomyopathy	0.000221	0.0018	CcSEcCtD
Methotrexate—Headache—Furosemide—dilated cardiomyopathy	0.000219	0.00179	CcSEcCtD
Methotrexate—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000217	0.00177	CcSEcCtD
Methotrexate—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000215	0.00175	CcSEcCtD
Methotrexate—Urticaria—Lisinopril—dilated cardiomyopathy	0.000209	0.0017	CcSEcCtD
Methotrexate—Nausea—Furosemide—dilated cardiomyopathy	0.000208	0.0017	CcSEcCtD
Methotrexate—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000208	0.00169	CcSEcCtD
Methotrexate—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000208	0.00169	CcSEcCtD
Methotrexate—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000194	0.00158	CcSEcCtD
Methotrexate—Asthenia—Lisinopril—dilated cardiomyopathy	0.000189	0.00154	CcSEcCtD
Methotrexate—Pruritus—Lisinopril—dilated cardiomyopathy	0.000186	0.00152	CcSEcCtD
Methotrexate—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00018	0.00147	CcSEcCtD
Methotrexate—Dizziness—Lisinopril—dilated cardiomyopathy	0.000174	0.00142	CcSEcCtD
Methotrexate—Vomiting—Lisinopril—dilated cardiomyopathy	0.000167	0.00136	CcSEcCtD
Methotrexate—Rash—Lisinopril—dilated cardiomyopathy	0.000166	0.00135	CcSEcCtD
Methotrexate—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000166	0.00135	CcSEcCtD
Methotrexate—Headache—Lisinopril—dilated cardiomyopathy	0.000165	0.00134	CcSEcCtD
Methotrexate—Nausea—Lisinopril—dilated cardiomyopathy	0.000156	0.00127	CcSEcCtD
Methotrexate—DHFR—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	9.87e-05	0.00122	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—SDHA—dilated cardiomyopathy	9.8e-05	0.00121	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	9.8e-05	0.00121	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—TAZ—dilated cardiomyopathy	9.63e-05	0.00119	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PSEN2—dilated cardiomyopathy	9.62e-05	0.00119	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—SOD2—dilated cardiomyopathy	9.59e-05	0.00119	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—SDHA—dilated cardiomyopathy	9.57e-05	0.00119	CbGpPWpGaD
Methotrexate—ABCC4—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	9.57e-05	0.00119	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	9.53e-05	0.00118	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	9.53e-05	0.00118	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TMPO—dilated cardiomyopathy	9.38e-05	0.00116	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ANKRD1—dilated cardiomyopathy	9.33e-05	0.00116	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	9.31e-05	0.00115	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	9.21e-05	0.00114	CbGpPWpGaD
Methotrexate—ALB—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	9.17e-05	0.00114	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—GPX1—dilated cardiomyopathy	9.15e-05	0.00113	CbGpPWpGaD
Methotrexate—PGD—Disease—NPPA—dilated cardiomyopathy	9.08e-05	0.00112	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VCL—dilated cardiomyopathy	9.01e-05	0.00112	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	8.96e-05	0.00111	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	8.96e-05	0.00111	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ANKRD1—dilated cardiomyopathy	8.94e-05	0.00111	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	8.92e-05	0.00111	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	8.86e-05	0.0011	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—LMNA—dilated cardiomyopathy	8.83e-05	0.00109	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	8.82e-05	0.00109	CbGpPWpGaD
Methotrexate—PGD—Disease—PSEN2—dilated cardiomyopathy	8.8e-05	0.00109	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—TAZ—dilated cardiomyopathy	8.77e-05	0.00109	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—SDHA—dilated cardiomyopathy	8.71e-05	0.00108	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	8.68e-05	0.00108	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	8.68e-05	0.00108	CbGpPWpGaD
Methotrexate—ABCC11—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	8.66e-05	0.00107	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	8.65e-05	0.00107	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	8.61e-05	0.00107	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	8.58e-05	0.00106	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	8.58e-05	0.00106	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—TAZ—dilated cardiomyopathy	8.4e-05	0.00104	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	8.38e-05	0.00104	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	8.33e-05	0.00103	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ANKRD1—dilated cardiomyopathy	8.2e-05	0.00102	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	8.15e-05	0.00101	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	8.15e-05	0.00101	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	8.07e-05	0.001	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	7.98e-05	0.000988	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—SDHA—dilated cardiomyopathy	7.93e-05	0.000982	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	7.91e-05	0.00098	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	7.76e-05	0.000961	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—TAZ—dilated cardiomyopathy	7.71e-05	0.000955	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—LMNA—dilated cardiomyopathy	7.7e-05	0.000954	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—CD36—dilated cardiomyopathy	7.64e-05	0.000946	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	7.62e-05	0.000943	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—SDHA—dilated cardiomyopathy	7.6e-05	0.000941	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	7.58e-05	0.000939	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	7.55e-05	0.000935	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	7.55e-05	0.000935	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	7.49e-05	0.000927	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ANKRD1—dilated cardiomyopathy	7.4e-05	0.000916	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—RAC1—dilated cardiomyopathy	7.3e-05	0.000904	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—CD36—dilated cardiomyopathy	7.28e-05	0.000901	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	7.27e-05	0.0009	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	7.25e-05	0.000898	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	7.07e-05	0.000875	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	7.06e-05	0.000874	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	7.02e-05	0.000869	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—SDHA—dilated cardiomyopathy	6.97e-05	0.000863	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—TAZ—dilated cardiomyopathy	6.96e-05	0.000862	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	6.76e-05	0.000837	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	6.74e-05	0.000835	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—GPX1—dilated cardiomyopathy	6.66e-05	0.000825	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	6.65e-05	0.000823	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	6.5e-05	0.000805	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—CD36—dilated cardiomyopathy	6.49e-05	0.000803	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ANKRD1—dilated cardiomyopathy	6.44e-05	0.000798	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—SDHA—dilated cardiomyopathy	6.29e-05	0.000779	CbGpPWpGaD
Methotrexate—FPGS—Disease—RAC1—dilated cardiomyopathy	6.21e-05	0.000769	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—ITGB1—dilated cardiomyopathy	6.07e-05	0.000752	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TAZ—dilated cardiomyopathy	6.06e-05	0.00075	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NPPA—dilated cardiomyopathy	5.99e-05	0.000742	CbGpPWpGaD
Methotrexate—AOX1—Disease—NPPA—dilated cardiomyopathy	5.85e-05	0.000725	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—AGT—dilated cardiomyopathy	5.84e-05	0.000723	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PSEN2—dilated cardiomyopathy	5.8e-05	0.000719	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ANKRD1—dilated cardiomyopathy	5.8e-05	0.000718	CbGpPWpGaD
Methotrexate—ABCC10—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.73e-05	0.00071	CbGpPWpGaD
Methotrexate—SLC46A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.73e-05	0.00071	CbGpPWpGaD
Methotrexate—AOX1—Disease—PSEN2—dilated cardiomyopathy	5.67e-05	0.000702	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—GPX1—dilated cardiomyopathy	5.66e-05	0.000701	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—GPX1—dilated cardiomyopathy	5.66e-05	0.000701	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TTN—dilated cardiomyopathy	5.53e-05	0.000685	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—CD36—dilated cardiomyopathy	5.52e-05	0.000683	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—CD36—dilated cardiomyopathy	5.52e-05	0.000683	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ANKRD1—dilated cardiomyopathy	5.51e-05	0.000682	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—SDHA—dilated cardiomyopathy	5.48e-05	0.000678	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TAZ—dilated cardiomyopathy	5.45e-05	0.000675	CbGpPWpGaD
Methotrexate—SLCO3A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.44e-05	0.000673	CbGpPWpGaD
Methotrexate—DHFR—Disease—NPPA—dilated cardiomyopathy	5.32e-05	0.000659	CbGpPWpGaD
Methotrexate—SLCO4C1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.19e-05	0.000642	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TAZ—dilated cardiomyopathy	5.18e-05	0.000642	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—CD36—dilated cardiomyopathy	5.18e-05	0.000641	CbGpPWpGaD
Methotrexate—DHFR—Disease—PSEN2—dilated cardiomyopathy	5.16e-05	0.000639	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ANKRD1—dilated cardiomyopathy	5.1e-05	0.000632	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—AGT—dilated cardiomyopathy	4.97e-05	0.000615	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AGT—dilated cardiomyopathy	4.97e-05	0.000615	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—SDHA—dilated cardiomyopathy	4.93e-05	0.00061	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—RAC1—dilated cardiomyopathy	4.88e-05	0.000604	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—RAF1—dilated cardiomyopathy	4.84e-05	0.000599	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—RAC1—dilated cardiomyopathy	4.84e-05	0.000599	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—ACTN2—dilated cardiomyopathy	4.8e-05	0.000594	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TAZ—dilated cardiomyopathy	4.8e-05	0.000594	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	4.79e-05	0.000593	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—SDHA—dilated cardiomyopathy	4.68e-05	0.00058	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	4.68e-05	0.000579	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	4.66e-05	0.000577	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	4.66e-05	0.000577	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	4.63e-05	0.000574	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—ITGB1—dilated cardiomyopathy	4.52e-05	0.00056	CbGpPWpGaD
Methotrexate—ALB—Vitamin B12 Metabolism—TNF—dilated cardiomyopathy	4.47e-05	0.000553	CbGpPWpGaD
Methotrexate—PGD—Disease—RAC1—dilated cardiomyopathy	4.42e-05	0.000548	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—GPX1—dilated cardiomyopathy	4.41e-05	0.000547	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.41e-05	0.000546	CbGpPWpGaD
Methotrexate—SLCO1C1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.35e-05	0.000538	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	4.34e-05	0.000537	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	4.33e-05	0.000536	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—CD36—dilated cardiomyopathy	4.3e-05	0.000532	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.25e-05	0.000527	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	4.2e-05	0.00052	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.14e-05	0.000513	CbGpPWpGaD
Methotrexate—FPGS—Disease—RAF1—dilated cardiomyopathy	4.12e-05	0.00051	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	4.08e-05	0.000505	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	4.08e-05	0.000505	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VCL—dilated cardiomyopathy	4.08e-05	0.000505	CbGpPWpGaD
Methotrexate—PGD—Metabolism—GPX1—dilated cardiomyopathy	4.04e-05	0.0005	CbGpPWpGaD
Methotrexate—PGD—Metabolism—CD36—dilated cardiomyopathy	3.93e-05	0.000487	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AGT—dilated cardiomyopathy	3.87e-05	0.000479	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—CD36—dilated cardiomyopathy	3.86e-05	0.000478	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.84e-05	0.000475	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	3.79e-05	0.00047	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.74e-05	0.000463	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.73e-05	0.000462	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—RAC1—dilated cardiomyopathy	3.64e-05	0.00045	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TNF—dilated cardiomyopathy	3.64e-05	0.00045	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AGT—dilated cardiomyopathy	3.54e-05	0.000438	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	3.39e-05	0.00042	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.36e-05	0.000417	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.34e-05	0.000414	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	3.33e-05	0.000412	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—EGFR—dilated cardiomyopathy	3.32e-05	0.000411	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.25e-05	0.000403	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—RAF1—dilated cardiomyopathy	3.23e-05	0.000401	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	3.21e-05	0.000397	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—RAF1—dilated cardiomyopathy	3.21e-05	0.000397	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	3.19e-05	0.000395	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ANKRD1—dilated cardiomyopathy	3.15e-05	0.00039	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	3.14e-05	0.000389	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NPPA—dilated cardiomyopathy	3.01e-05	0.000373	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.01e-05	0.000372	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TAZ—dilated cardiomyopathy	2.96e-05	0.000367	CbGpPWpGaD
Methotrexate—PGD—Disease—RAF1—dilated cardiomyopathy	2.93e-05	0.000363	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.93e-05	0.000363	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.93e-05	0.000363	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PSEN2—dilated cardiomyopathy	2.92e-05	0.000361	CbGpPWpGaD
Methotrexate—MTHFR—Disease—RAC1—dilated cardiomyopathy	2.92e-05	0.000361	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	2.89e-05	0.000358	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.86e-05	0.000354	CbGpPWpGaD
Methotrexate—SLC22A11—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.86e-05	0.000354	CbGpPWpGaD
Methotrexate—AOX1—Disease—RAC1—dilated cardiomyopathy	2.85e-05	0.000353	CbGpPWpGaD
Methotrexate—FPGS—Disease—EGFR—dilated cardiomyopathy	2.82e-05	0.00035	CbGpPWpGaD
Methotrexate—SLC16A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.8e-05	0.000347	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.78e-05	0.000345	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	2.76e-05	0.000342	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	2.76e-05	0.000342	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SDHA—dilated cardiomyopathy	2.68e-05	0.000331	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—GPX1—dilated cardiomyopathy	2.66e-05	0.00033	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.64e-05	0.000327	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GPX1—dilated cardiomyopathy	2.6e-05	0.000322	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—CD36—dilated cardiomyopathy	2.59e-05	0.000321	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	2.59e-05	0.000321	CbGpPWpGaD
Methotrexate—DHFR—Disease—RAC1—dilated cardiomyopathy	2.59e-05	0.000321	CbGpPWpGaD
Methotrexate—SLC22A7—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.59e-05	0.000321	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—CD36—dilated cardiomyopathy	2.53e-05	0.000314	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.51e-05	0.00031	CbGpPWpGaD
Methotrexate—SLCO1B3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.46e-05	0.000305	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—RAF1—dilated cardiomyopathy	2.41e-05	0.000299	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GPX1—dilated cardiomyopathy	2.37e-05	0.000293	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	2.35e-05	0.00029	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AGT—dilated cardiomyopathy	2.33e-05	0.000289	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CD36—dilated cardiomyopathy	2.3e-05	0.000285	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AGT—dilated cardiomyopathy	2.28e-05	0.000282	CbGpPWpGaD
Methotrexate—ABCC3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.22e-05	0.000275	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—EGFR—dilated cardiomyopathy	2.2e-05	0.000272	CbGpPWpGaD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.18e-05	0.00027	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GPX1—dilated cardiomyopathy	2.16e-05	0.000267	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	2.12e-05	0.000262	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CD36—dilated cardiomyopathy	2.1e-05	0.00026	CbGpPWpGaD
Methotrexate—ABCC4—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.09e-05	0.000259	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	2.08e-05	0.000258	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AGT—dilated cardiomyopathy	2.07e-05	0.000257	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GPX1—dilated cardiomyopathy	2.06e-05	0.000256	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	2.05e-05	0.000254	CbGpPWpGaD
Methotrexate—PGD—Disease—EGFR—dilated cardiomyopathy	2.01e-05	0.000249	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CD36—dilated cardiomyopathy	2.01e-05	0.000249	CbGpPWpGaD
Methotrexate—MTHFR—Disease—RAF1—dilated cardiomyopathy	1.93e-05	0.00024	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.93e-05	0.000239	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GPX1—dilated cardiomyopathy	1.89e-05	0.000235	CbGpPWpGaD
Methotrexate—AOX1—Disease—RAF1—dilated cardiomyopathy	1.89e-05	0.000234	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AGT—dilated cardiomyopathy	1.89e-05	0.000234	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CD36—dilated cardiomyopathy	1.84e-05	0.000228	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.82e-05	0.000225	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AGT—dilated cardiomyopathy	1.81e-05	0.000224	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.76e-05	0.000218	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—CD36—dilated cardiomyopathy	1.75e-05	0.000216	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.74e-05	0.000215	CbGpPWpGaD
Methotrexate—DHFR—Disease—RAF1—dilated cardiomyopathy	1.72e-05	0.000213	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GPX1—dilated cardiomyopathy	1.71e-05	0.000212	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CD36—dilated cardiomyopathy	1.66e-05	0.000206	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AGT—dilated cardiomyopathy	1.66e-05	0.000206	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.65e-05	0.000205	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—RAC1—dilated cardiomyopathy	1.65e-05	0.000204	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.63e-05	0.000202	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.59e-05	0.000197	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.53e-05	0.00019	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AGT—dilated cardiomyopathy	1.5e-05	0.000186	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GPX1—dilated cardiomyopathy	1.49e-05	0.000184	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RAC1—dilated cardiomyopathy	1.47e-05	0.000182	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CD36—dilated cardiomyopathy	1.45e-05	0.000179	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.43e-05	0.000177	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	1.43e-05	0.000177	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	1.36e-05	0.000169	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GPX1—dilated cardiomyopathy	1.34e-05	0.000166	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—dilated cardiomyopathy	1.33e-05	0.000164	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AGT—dilated cardiomyopathy	1.3e-05	0.000162	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CD36—dilated cardiomyopathy	1.3e-05	0.000162	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—dilated cardiomyopathy	1.3e-05	0.000161	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GPX1—dilated cardiomyopathy	1.27e-05	0.000158	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CD36—dilated cardiomyopathy	1.24e-05	0.000153	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—dilated cardiomyopathy	1.18e-05	0.000146	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	1.18e-05	0.000146	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AGT—dilated cardiomyopathy	1.17e-05	0.000145	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CD36—dilated cardiomyopathy	1.15e-05	0.000142	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AGT—dilated cardiomyopathy	1.12e-05	0.000138	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—RAF1—dilated cardiomyopathy	1.09e-05	0.000135	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AGT—dilated cardiomyopathy	1.03e-05	0.000128	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RAF1—dilated cardiomyopathy	9.73e-06	0.000121	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	9.45e-06	0.000117	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	8.28e-06	0.000103	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GPX1—dilated cardiomyopathy	7.27e-06	9e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CD36—dilated cardiomyopathy	7.08e-06	8.77e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—dilated cardiomyopathy	6.67e-06	8.26e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AGT—dilated cardiomyopathy	6.38e-06	7.9e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	6.37e-06	7.89e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CD36—dilated cardiomyopathy	6.2e-06	7.68e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AGT—dilated cardiomyopathy	5.59e-06	6.92e-05	CbGpPWpGaD
